Proparacaine
- Generic Name
- Proparacaine
- Brand Names
- Alcaine, Lenalidomide Krka d.d. Novo mesto (previously Lenalidomide Krka), Revlimid, Lenalidomide Mylan, Lenalidomide Krka (previously Lenalidomide Krka d.d. Novo mesto), Lenalidomide Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C16H26N2O3
- CAS Number
- 499-67-2
- Unique Ingredient Identifier
- B4OB0JHI1X
- Background
Proparacaine is a topical anesthetic drug of the amino ester group. It is found in ophthalmic solutions at a concentration of 0.5% as the hydrochloride salt.
- Indication
Used as a local (ophthalmic) anesthetic.
- Associated Conditions
- Chronic Lymphocytic Leukemia (CLL) - Refractory, Follicular Lymphoma ( FL), Mantle Cell Lymphoma (MCL), Marginal Zone Lymphoma (MZL), Multiple Myeloma (MM), Myelodysplastic Syndrome, Primary Amyloidosis, Refractory Diffuse Large B Cell Lymphoma (DLBCL)
- Associated Therapies
- Local Anaesthesia therapy
Study on the Efficacy and Safety of Low-dose CTX as Maintenance Therapy for MM Unsuitable for Transplantation
- Conditions
- Newly Diagnosed Multiple Myeloma
- Interventions
- First Posted Date
- 2024-03-21
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- Jinling Hospital, China
- Target Recruit Count
- 80
- Registration Number
- NCT06324266
- Locations
- 🇨🇳
Jinling Hospital, Nanjing, Jiangsu, China
A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma
- Conditions
- Relapsed or Refractory Follicular Lymphoma
- Interventions
- First Posted Date
- 2024-03-15
- Last Posted Date
- 2024-03-15
- Lead Sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Target Recruit Count
- 300
- Registration Number
- NCT06313996
Study of Mosunetuzumab Plus Lenalidomide Compared to Anti-CD20 Anti-body + Chemotherapy in Follicular Lymphoma FLIPI2-5
- Conditions
- Follicular Lymphoma
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-10-11
- Lead Sponsor
- The Lymphoma Academic Research Organisation
- Target Recruit Count
- 790
- Registration Number
- NCT06284122
- Locations
- 🇫🇷
HOPITAL HENRI MONDOR - Unité Hémopathies Lymphoïdes, Créteil, France
🇫🇷GUSTAVE ROUSSY CANCER CAMPUS GRAND PARIS - Département Médecine Oncologique, Villejuif, France
🇫🇷CH ANNECY GENEVOIS - SITE D'ANNECY - Service Hématologie, Pringy, France
Acute Lymphoblastic Leukaemia Related to Lenalidomide (LenALL)
- Conditions
- Cancer
- First Posted Date
- 2024-02-09
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- University Hospital, Caen
- Target Recruit Count
- 300
- Registration Number
- NCT06251648
- Locations
- 🇫🇷
CHU de Caen, Caen, France
Optimizing Reversal of HIV Latency With Combination Therapy
- Conditions
- Hiv
- Interventions
- First Posted Date
- 2024-02-05
- Last Posted Date
- 2024-02-05
- Lead Sponsor
- Erasmus Medical Center
- Target Recruit Count
- 49
- Registration Number
- NCT06240520
- Locations
- 🇳🇱
Erasmus Medical Centre, Rotterdam, Zuid Holland, Netherlands
🇳🇱Amsterdam University Medical Center, Amsterdam, Netherlands
🇳🇱University Medical Center Utrecht, Utrecht, Netherlands
Prevention of Anthracycline-Induced Cardiac Dysfunction With Dexrazoxane in Patients With Diffuse Large-B Cell Lymphoma
- Conditions
- DLBCL - Diffuse Large B Cell Lymphoma
- Interventions
- First Posted Date
- 2024-01-23
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Stichting Hemato-Oncologie voor Volwassenen Nederland
- Target Recruit Count
- 324
- Registration Number
- NCT06220032
- Locations
- 🇳🇱
NL-Breda-AMPHIA, Breda, Netherlands
🇳🇱NL-Almelo-ZGTALMELO, Almelo, Netherlands
🇳🇱NL-Amstelveen-AMSTELLAND, Amstelveen, Netherlands
Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy with Elranatamab in Patients with High-risk Multiple Myeloma
- Conditions
- Post-transplant MRD-guided Maintenance TherapyMultiple MyelomaPre-transplant Purging
- Interventions
- Procedure: Stem cell transplant
- First Posted Date
- 2024-01-17
- Last Posted Date
- 2025-02-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 40
- Registration Number
- NCT06207799
- Locations
- 🇺🇸
MD Anderson Cancer Center, Houston, Texas, United States
Pilot Study Using Changes in Serum BCMA to Determine Disease Progression in Multiple Myeloma
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2024-01-17
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Oncotherapeutics
- Target Recruit Count
- 30
- Registration Number
- NCT06209606
- Locations
- 🇺🇸
Berenson Cancer Center, West Hollywood, California, United States
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Previously Untreated Follicular Lymphoma
- Conditions
- Follicular Lymphoma (FL)
- Interventions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Genmab
- Target Recruit Count
- 1095
- Registration Number
- NCT06191744
- Locations
- 🇫🇷
Hôpital Saint-Louis /ID# 260509, Paris, France
🇫🇷Clinique Sainte-Anne /ID# 261528, Strasbourg, France
🇨🇳Zhujiang Hospital of Southern Medical University /ID# 260558, Guangzhou, Guangdong, China
Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2024-01-05
- Last Posted Date
- 2024-04-23
- Lead Sponsor
- Stichting European Myeloma Network
- Target Recruit Count
- 200
- Registration Number
- NCT06189833
- Locations
- 🇬🇷
St Savvas Cancer Hospital, Athens, Greece
🇩🇪Universitätsklinikum Hamburg - Eppendorf, Hamburg, Germany
🇦🇹Innsbruck Medical University, Innsbruck, Austria
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.